Singapore, Dec 09, 2011: DKSH, the leading Market Expansion Services provider with a focus on Asia, is expanding its repackaging facility for its healthcare business in Hong Kong to meet the growing needs of business partners.
The new facility now boasts a doubled repackaging area, increased from 4,000 to 8,000 square feet. The repackaging production lines have been increased to a total of nine, eight in the air-conditioned room (15 to 25 °C), and one in the cold room (2 to 8 °C), catering for different requirements. The storage area has also been doubled from 1,000 to over 2,000 square feet, and daily output capacity increased to over 30,000 units with the extended skilled manpower.
DKSH offers secondary packaging services such as labeling, insert/outer box exchange, shrink wrapping, product condition sorting, and packaging material management for a wide range of pharmaceutical products, narcotic drugs, cold chain products, medical devices, clinical trial products, traditional Chinese medicines, and consumer health products. The operation is fully compliant with the Good Manufacturing Practice (GMP), Good Storage and Distribution Practice (GSDP), ISO 9001, and ISO 13485 standards. An independent quality control team is in place to monitor the redressing process and is responsible for inspection and quality assurance of repacked products.
"To meet the growing needs of our healthcare business partners in pharmaceutical, over-the-counter (OTC), consumer health, and medical devices, our extended repackaging facility serves to help them achieve their expansion goals," said Richard Holloway, Vice President, DKSH Business Unit Healthcare, Hong Kong. "Partnerships with Market Expansion Services providers allow pharmaceutical companies to bring new drugs and healthcare products faster and more cost efficiently to the market. With increasing purchasing power and longer life expectancy making up the consumer background, it is easy to see the need for corresponding higher quality healthcare and substantial growth potential of these markets."
Source: BioSpectrum Bureau